Pain patients and people who lost family members to addiction were among the groups represented at an FDA hearing on a petition on the labeling of opioid drugs. A petition from Physicians for Responsible Opioid Prescribing calls for restrictions on the marketing and use of opioid painkillers, including for moderate noncancer pain. Other groups said the proposal could block access to opioid drugs for patients with legitimate pain and that there are challenges in attempting to distinguish cancer pain and noncancer pain due to the long-term complications of the disease.

Related Summaries